Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

06/22/2021 | 09:25pm EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the ''Indicative Announcement regarding the Registration Progress of Pharmaceutical Product of Fosun Kite Biotechnology Co., Ltd.*'' published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

23 June 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

  • for identification purposes only

Stock code: 600196

Stock abbreviation: Fosun Pharma

Announcement No.: Lin 2021- 095

Bond code: 143020

Bond abbreviation:17 Fosun 01

Bond code: 143422

Bond abbreviation:18 Fosun 01

Bond code: 155067

Bond abbreviation:18 Fosun 02

Bond code: 155068

Bond abbreviation:18 Fosun 03

Bond code: 175708

Bond abbreviation: 21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Indicative Announcement regarding the Registration Progress of Pharmaceutical Product of Fosun Kite Biotechnology Co., Ltd.*

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

Important (definitions are the same as the text)

  1. As at the date of this announcement, the Company indirectly holds 50% equity interest in Fosun Kite, and Fosun Kite is a joint venture of the Company.
  2. As at the time of this announcement, the certificate of drug registration approval for the CAR-T Cell Therapy Product has yet to be received. The registration of the Product is subject to the official certificate of drug registration approval to be issued and the information contained in such registration certificate shall prevail.
  3. Due to the industry characteristics of pharmaceutical products, the sale of the Product after the approval may be affected by factors including, among others, market conditions and sale channels, which will have greater uncertainty.

2

I. Overview

On 22 June 2021, as indicated in the public information on the website of the National Medical Products Administration ("NMPA") (http://www.nmpa.gov.cn), the status of marketing registration approval for the autologous CD19-directedCAR-T cell therapy Axicabtagene Ciloleucel (code FKC876, the"Product"or "CAR-TCell Therapy Product") of Fosun Kite Biotechnology Co., Ltd.* (復星凱特生物科技有限公司) ("Fosun Kite", a 50% equity interest of which is held by Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復星醫藥產業發展有限公司), a subsidiary of the Company), an investee company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company"), was updated to "the certificate of drug approval to be collected" with the approval number of "Guo Yao Zhun Zi S20210019".

II. Basic Information of the Product

The Product is produced following the technology transfer of the autologous CD19-directedCAR-T cell therapy (Yescarta® ) of Kite, a Gilead company in the United States and proposed to carry out localized production in PRC (excluding Hong Kong, Macau and Taiwan). The indication for the registration application of the Product is for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-gradeB-cell lymphoma and DLBCL arising from follicular lymphoma.

Fosun Kite initiated the technology transfer of the Product from Kite and obtained technical and commercial rights in Chinese Mainland, Hong Kong SAR and Macau SAR.

3

  1. Impact on the Listed Company and Risk Warning
  1. As at the date of this announcement, the Company indirect holds 50% equity interest in Fosun Kite, and Fosun Kite is a joint venture of the Company.
  2. As at the time of this announcement, the certificate of drug registration approval for the CAR-T Cell Therapy Product has yet to be received. The registration of the Product is subject to the official certificate of drug registration approval to be issued and the information contained in such registration certificate shall prevail.
  3. Due to the industry characteristics of pharmaceutical products, the sale of the Product after the approval may be affected by factors including, among others, market conditions and sale channels, which will have greater uncertainty.

Investors should be aware of the investment risks.

Announcement is hereby given.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. * 23 June 2021

* for identification purposes only

4

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 23 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 June 2021 01:24:03 UTC.


ę Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
06:22aSHANGHAI FOSUN PHARMACEUTICAL : Announcement on the approval from csrc for the p..
PU
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
More news
Financials
Sales 2021 40 184 M 6 220 M 6 220 M
Net income 2021 4 372 M 677 M 677 M
Net Debt 2021 15 917 M 2 464 M 2 464 M
P/E ratio 2021 48,5x
Yield 2021 0,63%
Capitalization 198 B 30 653 M 30 658 M
EV / Sales 2021 5,33x
EV / Sales 2022 4,71x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 82,39 CNY
Average target price 57,08 CNY
Spread / Average Target -30,7%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman